Physician profile
Wen Han
NPI 1104020312
$56,649.40
in general payments reported to CMS, 2019-2025
15 companies · $62.11 in 2025
The $62.11 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $6,594 · 2021: $25K · 2022: $214 · 2023: $394 · 2024: $570 · 2025: $62.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,025.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $33,812.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18,561.71 | 2019-2021 | |
| Lilly USA, LLC | $2,496.66 | 2019-2024 | Mounjaro |
| Esperion Therapeutics, INC. | $432.65 | 2020-2021 | |
| Amgen INC. | $367.40 | 2019-2024 | Evenity, Prolia |
| Beta Bionics, INC. | $279.50 | 2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $190.07 | 2019-2022 | |
| Dexcom, INC. | $188.23 | 2024-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $102.07 | 2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $85.67 | 2020-2021 | |
| Amarin Pharma, INC. | $55.89 | 2019-2020 | |
| Radius Health, INC. | $27.57 | 2020 | |
| Madrigal Pharmaceuticals | $23.58 | 2025 | Rezdiffra |
| Silk Road Medical, INC. | $13.08 | 2019 | |
| Medtronic Minimed, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wen Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.